Speakers - Boston Symposium 2019
Senior Director, Research Service Division
After NeoGenesis was acquired by Schering-Plough, he joined the HTS group of Schering-Plough in 2006, where he supervised assay development, screening, data analysis, and post-HTS followup for a wide variety of target classes from diverse disease areas in both medium throughput (96/384) and high-throughput (1536) formats.
After the acquisition of Schering-Plough by Merck, Dr. Agnihotri joined the In Vitro Pharmacology group at Merck Research Labs in Kenilworth, NJ in 2010. He led a team in the Biochemistry/Biophysics group to develop assays and determine mode of action for multiple protease targets and then moved to the Screening Operations team in 2012 where he led a team of compound management scientists, automation engineers, and biologists. He left Merck in June 2014 to join WuXi AppTec, and is currently Senior Director in the Research Service Division.
Dr. Agnihotri’s skills span the areas of biochemistry and enzymology, as well as medium and high-throughput screening, automation, data analysis and reporting. In his current role, he helped in the establishment of WuXi AppTec labs in New Jersey and is leading biochemical/biophysical assay development and optimization.
Lead, Digital Capability Management, Leads Discovery and Optimization
Johannes H. Voigt
Directory, Computational Chemistry
Hetal Patel, M.S.
Senior Scientist, Data II